Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02776215 · ClinicalTrials.gov registry record · Phase 1
Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents
A Phase 1 study of Autism Spectrum Disorder and Smith-Magenis Syndrome, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT02776215: Completed Phase 1 study of Autism Spectrum Disorder and Smith-Magenis Syndrome, sponsored by Vanda Pharmaceuticals.
NCT02776215 is a Phase 1 study of Autism Spectrum Disorder and Smith-Magenis Syndrome that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 24 participants, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02776215, a Phase 1 study of Autism Spectrum Disorder and Smith-Magenis Syndrome, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
Open-label Study to Investigate the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents.
Conditions Studied
Interventions
- DRUG tasimelteon
Study Locations (1)
Maryland
- Parexel Early Phase Clinical Unit - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-10-04 |
| Est. Completion | 2017-12-20 |
| Phase | Phase 1 |
What the finished NCT02776215 record still lists
NCT02776215 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (82% lower).
The record links to 4 conditions, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 1 intervention - of which tasimelteon is the first listed.
NCT02776215 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT02776215 about?
NCT02776215 is a clinical study titled "Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents". Open-label Study to Investigate the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents.
What is the current status of trial NCT02776215?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2016-10-04. Estimated completion is 2017-12-20.
What conditions does trial NCT02776215 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder, Smith-Magenis Syndrome, Non-24 Hour Sleep-Wake Disorder, Circadian Rhythm Sleep Disorders.
What interventions are being tested in trial NCT02776215?
The interventions under investigation include: tasimelteon (DRUG).
Who is sponsoring clinical trial NCT02776215?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02776215 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02776215's enrollment target sits among peer trials
24 188th of 224 higher than 31 of 224 other Autism Spectrum Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autism Spectrum Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cannabidiol (CBD) in Adults With ASD
RECRUITING · Phase 1
-
Combination Probiotic: BB-12 With LGG (Different Doses) in Treating Children With Autism Spectrum Disorder
RECRUITING · Phase 1
-
Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study
RECRUITING · Phase 1
-
Safety, Tolerability and Pharmacokinetics of Lumateperone in Pediatric Patients With Autism Spectrum Disorder
RECRUITING · Phase 1
-
Autologous Umbilical Cord Blood Infusion for Children With Autism Spectrum Disorder (ASD)
COMPLETED · Phase 1
-
A Study to Evaluate Scales for Repetitive and Restricted Behaviors in Children, Adolescents, and Adults With Autism Spectrum Disorder (ASD)
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI